Health & bio
FDA accelerates Avlayah for Hunter Syndrome
Drugs.com notes FDA accelerated approval of tividenofusp alfa-eknm (Avlayah) on March 25 for Hunter Syndrome (MPS II).
Primary sources · 1
Drugs.com notes FDA accelerated approval of tividenofusp alfa-eknm (Avlayah) on March 25 for Hunter Syndrome (MPS II).
7 must-reads · 17 fields · tracked storylines delivered to your inbox daily. Pick only the fields you want; unsubscribe anytime.